ConductScience.org, home

Trial · NCT01450137

Participant flow12

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Up to Week 12STARTEDTocilizumab20
Up to Week 12STARTEDPlacebo10
Up to Week 12COMPLETEDTocilizumab18
Up to Week 12COMPLETEDPlacebo7
Up to Week 12NOT COMPLETEDTocilizumab2
Up to Week 12NOT COMPLETEDPlacebo3
Week 12 to Study EndSTARTEDTocilizumab18
Week 12 to Study EndSTARTEDPlacebo7
Week 12 to Study EndCOMPLETEDTocilizumab18
Week 12 to Study EndCOMPLETEDPlacebo5
Week 12 to Study EndNOT COMPLETEDTocilizumab0
Week 12 to Study EndNOT COMPLETEDPlacebo2

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01450137/flow